Table 1 |
|||||
| Clinical and pathologic characteristics of 118 endometrioid endometrial cancer patients and their association to Trop-2 protein expression | |||||
| Trop-2 protein expression | |||||
| Variable | n | Score≤1 n (%) | Score=2 n (%) | Score=3 n(%) | p value* |
| Age at diagnosis | |||||
| <65 | 51 | 22 (43.1) | 17 (33.3) | 12 (23.5) | |
| 0.89 | |||||
| ≥65 | 67 | 28 (41.8) | 26 (38.8) | 13 (19.4) | |
| FIGO stage(2009 criteria) | |||||
| I-II | 86 | 37 (43) | 33 (38.4) | 16 (18.6) | |
| 0.56 | |||||
| III-IV | 22 | 8 (36.4) | 6 (27.3) | 8 (36.4) | |
| Unknown | 10 | 5 (50) | 4 (40) | 1 (10) | |
| WHO grading | |||||
| Grade 1 | 34 | 21 (61.8) | 11 (32.4) | 2 (5.9) | |
| 0.024 | |||||
| Grade 2-3 | 84 | 29 (34.5) | 32 (38.1) | 23 (27.4) | |
| Myometrial invasion | |||||
| M0+M1 | 55 | 26 (47.3) | 22 (40) | 7 (12.7) | |
| 0.08 | |||||
| M2 | 63 | 24 (38.1) | 21 (33.3) | 18 (28.6) | |
| Lymph node status | |||||
| Negative | 79 | 35 (44.3) | 28 (35.4) | 16 (20.3) | |
| 0.69 | |||||
| Positive | 15 | 5 (33.3) | 5 (33.3) | 5 (33.3) | |
| Unknown | 24 | 10 (41.7) | 10 (41.7) | 4 (16.7) | |
| Cervical involvement | |||||
| Absent | 83 | 37 (44.6) | 33 (39.8) | 13 (15.7) | |
| Glandular involvement | 16 | 10 (62.5) | 4 (25) | 2 (12.5) | <0.01$ |
| Stromal involvement | 18 | 3 (16.7) | 6 (33.3) | 9 (50) | |
| Unknown | 1 | 0 (0) | 0 (0) | 1 (100) | |
| Adnexal involvement | |||||
| Negative | 108 | 45 (41.7) | 42 (38.9) | 21 (19.4) | 0.97 |
| Positive | 9 | 5 (55.6) | 0 (0) | 4 (44.4) | |
| Unknown | 1 | 0 (0) | 1 (100) | 0 (0) | |
| Peritoneal cytology | |||||
| Negative | 100 | 40 (40) | 37 (37) | 23 (23) | |
| 0.44 | |||||
| Positive | 8 | 4 (50) | 2 (25) | 2 (25) | |
| Unknown | 10 | 6 (60) | 4 (40) | 0 (0) | |
| Lymphovascular invasion | |||||
| Absent | 48 | 22 (45.8) | 20 (41.7) | 6 (12.5) | |
| 0.13 | |||||
| Present | 56 | 21 (37.5) | 20 (35.7) | 15 (26.8) | |
| Unknown | 14 | 7 (50) | 3 (21.4) | 4 (28.6) | |
| Adjuvant Treatment | |||||
| None | 57 | 31 (54.4) | 20 (35.1) | 6 (10.5) | |
| Radiotherapy | 36 | 12 (33.3) | 13 (36.1) | 11 (30.6) | |
| Chemotherapy | 8 | 3 (37.5) | 1 (12.5) | 4 (50.0) | 0.094$ |
| Radiotherapy+Chemotherapy | 9 | 2 (22.2) | 5 (55.6) | 2 (22.2) | |
| Unknown | 8 | 5 (62.5) | 2 (25.0) | 1 (12.5) | |
| Parity | |||||
| Nulliparity | 22 | 10 (45.5) | 7 (31.8) | 5 (22.7) | |
| 0.72 | |||||
| Multiparity | 88 | 34 (38.6) | 35 (39.8) | 19 (21.6) | |
| Unknown | 8 | 6 (75) | 1 (12.5) | 1 (12.5) | |
| Body Mass Index | |||||
| <25 | 36 | 12 (33.3) | 14 (38.9) | 10 (27.8) | |
| 0.58 | |||||
| ≥25 | 64 | 27 (42.2) | 24 (37.5) | 13 (20.3) | |
| Unknown | 18 | 11 (61.1) | 5 (27.8) | 2 (11.1) | |
| Hypertension | |||||
| Negative | 48 | 18 (37.5) | 18 (37.5) | 12 (25) | |
| 0.26 | |||||
| Positive | 63 | 27 (42.9) | 24 (38.1) | 12 (19) | |
| Unknown | 7 | 5 (71.4) | 1 (14.3) | 1 (14.3) | |
| Diabetes | |||||
| Negative | 96 | 38 (39.6) | 39 (40.6) | 19 (19.8) | |
| 0.95 | |||||
| Positive | 15 | 8 (53.3) | 2 (13.3) | 5 (33.3) | |
| Unknown | 7 | 4 (57.1) | 2 (28.6) | 1 (14.3) | |
| Menopausal Status | |||||
| Premenopausal | 18 | 7 (38.9) | 5 (27.8) | 6 (33.3) | |
| 0.33 | |||||
| Postmenopausal | 94 | 39 (41.5) | 37 (39.4) | 18 (19.1) | |
| Unknown | 6 | 4 (66.7) | 1 (16.7) | 1 (16.7) | |
| Smoking | |||||
| Negative | 82 | 29 (35.4) | 35 (42.7) | 18 (22) | |
| 0.91 | |||||
| Positive | 20 | 9 (45) | 6 (30) | 5 (25) | |
| Unknown | 16 | 12 (75) | 2 (12.5) | 2 (12.5) | |
* Exact Wilcoxon-Mann–Whitney test.
$ Non-parametric ANOVA.
Unknown values were considered as missing and therefore excluded from the statistical analysis.
Bignotti et al. BMC Clinical Pathology 2012 12:22 doi:10.1186/1472-6890-12-22
